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Abstract
Background: Techniques enabling targeted re-sequencing of the protein coding sequences of the human
genome on next generation sequencing instruments are of great interest. We conducted a systematic comparison
of the solution-based exome capture kits provided by Agilent and Roche NimbleGen. A control DNA sample was
captured with all four capture methods and prepared for Illumina GAII sequencing. Sequence data from additional
samples prepared with the same protocols were also used in the comparison.
Results: We developed a bioinformatics pipeline for quality control, short read alignment, variant identification and
annotation of the sequence data. In our analysis, a larger percentage of the high quality reads from the NimbleGen
captures than from the Agilent captures aligned to the capture target regions. High GC content of the target
sequence was associated with poor capture success in all exome enrichment methods. Comparison of mean allele
balances for heterozygous variants indicated a tendency to have more reference bases than variant bases in the
heterozygous variant positions within the target regions in all methods. There was virtually no difference in the
genotype concordance compared to genotypes derived from SNP arrays. A minimum of 11× coverage was
required to make a heterozygote genotype call with 99% accuracy when compared to common SNPs on genome-
wide association arrays.
Conclusions: Libraries captured with NimbleGen kits aligned more accurately to the target regions. The updated
NimbleGen kit most efficiently covered the exome with a minimum coverage of 20×, yet none of the kits captured
all the Consensus Coding Sequence annotated exons.
Background
The capacity of DNA sequencing has increased expo-
nentially in the past few years. Sequencing of a whole
human genome, which previously took years and cost
millions of dollars, can now be achieved in weeks [1-3].
However, as pricing of whole-genome sequencing has
not yet reached the US$1000 range, methods for focus-
ing on the most informative and well-annotated regions
- the protein coding sequences - of the genome have
been developed.
Albert et al. [4] introduced a method to enrich geno-
mic loci for next generation re-sequencing using Roche
NimbleGen oligonucleotide arrays in 2007, just prior to
Hodges and collaborators [5], who applied the arrays to
capture the full human exome. Since then, methods
requiring less hands-on work and a smaller amount of
input DNA have been under great demand. A solution-
based oligonucleotide hybridization and capture method
based on Agilent’s biotinylated RNA baits was described
by Gnirke et al. in 2009 [6]. Agilent SureSelect Human
All Exon capture was the first commercial sample pre-
paration kit on the market utilizing this technique, soon
followed by Roche NimbleGen with the SeqCap EZ
Exome capture system [7]. The first authors demonstrat-
ing the kits’ capability to identify genetic causes of dis-
ease were Hoischen et al. (Agilent SureSelect) [8] and
Harbour et al. (NimbleGen SeqCap) [9] in 2010. To
date, exome sequencing verges on being the standard
approach in studies of monogenic disorders, with
increasing interest in studies of more complex diseases
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core laboratory is thus: ‘Which exome capture method
should I use?’
The sample preparation protocols for the methods are
highly similar; the greatest differences are in the capture
probes used, as Agilent uses 120-bp long RNA baits,
whereas NimbleGen uses 60- to 90-bp DNA probes.
Furthermore, Agilent SureSelect requires only a 24-hour
hybridization, whereas NimbleGen recommends an up
to 72-hour incubation. No systematic comparison of the
performance of these methods has yet been published
despite notable differences in probe design, which could
significantly affect hybridization sensitivity and specifi-
city and thus the kits’ ability to identify genetic
variation.
Here we describe a comprehensive comparison of the
first solution-based whole exome capture methods on
the market; Agilent SureSelect Human All Exon and its
updated version Human All Exon 50 Mb, and Roche
NimbleGen SeqCap EZ Exome and its updated version
SeqCap EZ v2.0. We have compared pairwise the perfor-
mance of the first versions and the updated versions of
these methods on capturing the targeted regions and
exons of the Consensus Coding Sequence (CCDS) pro-
ject, their ability to identify and genotype known and
novel single nucleotide variants (SNVs) and to capture
small insertion-deletion (indel) variants. In addition, we
present our variant-calling pipeline (VCP) that we used
to analyze the data.
Results
Capture designs
The probe designs of Agilent SureSelect Human All
Exon capture kits (later referred to as Agilent SureSelect
and Agilent SureSelect 50 Mb) and NimbleGen SeqCap
EZ Exome capture kits (later referred to as NimbleGen
SeqCap and NimbleGen SeqCap v2.0) are compared in
Figure 1 and Additional file 1 with the CCDS project
exons [10] and the known exons from the UCSC Gen-
ome Browser [11]. Agilent SureSelect included 346,500
and SureSelect 50 Mb 635,250 RNA probes of 120 bp in
length targeting altogether 37.6 Mb and 51.6 Mb of
sequence, respectively. Both NimbleGen SeqCap kits
had approximately 2.1 million DNA probes varying
from 60 bp to 90 bp, covering 33.9 Mb in the SeqCap
kit and 44.0 Mb in the SeqCap v2.0 kit in total. The
Agilent SureSelect design targeted about 13,300 CCDS
exon regions (21,785 individual exons) more than the
NimbleGen SeqCap design (Figure 1a and Table 1).
With the updated exome capture kits, Agilent SureSelect
50 Mb targeted 752 CCDS exon regions more than
NimblGen SeqCap v2.0, but altogether it had 17,449 tar-
geted regions and 1,736 individual CCDS exons more
than the latter (Figure 1b). All of the exome capture kits
targeted nearly 80% of all microRNAs (miRNAs) in
miRBase v.15 at the minimum. The GC content of the
probe designs of both vendors was lower than that of
the whole CCDS exon regions (Table 1).Only Agilent
avoided repetitive regions in their probe design (Repeat-
Masker April 2009 freeze). Neither of the companies
had adjusted their probe designs according to the copy
number variable sequences (Database of Genomic Var-
iants, March 2010 freeze).
Variant-calling pipeline
A bioinformatics pipeline for quality control, short read
alignment, variant identification and annotation (named
VCP) was developed for the sequence data analyses.
Existing software were combined with in-house devel-
oped algorithms and file transformation programs to
establish an analysis pipeline with simple input files,
minimum hands-on work with the intermediate data
and an extensive variety of sequencing results for all
kinds of next-generation DNA sequencing experiments.
In the VCP, sequence reads in FASTQ format were first
filtered for quality. Sequence alignment was then per-
formed with Burrows-Wheeler Aligner (BWA) [12], fol-
lowed by duplicate removal. Variant calling was done
with SAMtools’ pileup [13], with an in-house developed
algorithm using allele qualities for SNV calling, and with
read end anomaly (REA) calling (see the ‘Computational
methods’ section for details). In addition to tabular for-
mats, result files were given in formats applicable for
visualization in the Integrative Genomics Viewer [14] or
other sequence alignment visualization interfaces. An
o v e r v i e wo ft h eV C Pi sg i v e ni nF i g u r e2 .I na d d i t i o n ,
identification of indels with Pindel [15], visualization of
anomalously mapping paired-end (PE) reads with Circos
[16] and de novo alignment of un-aligned reads with
Velvet [17] were included in the VCP, but these analysis
options were not used in this study.
Sequence alignment
We obtained 4.7 Gb of high quality sequence with Agilent
SureSelect and 5.1 Gb with NimbleGen SeqCap, of which
81.4% (Agilent) and 84.4% (NimbleGen) mapped to the
human reference sequence hg19 (GRCh37). For the
updated kits the obtained sequences were 5.6 Gb for the
Agilent SureSelect 50 Mb and 7.0 Gb for the NimbleGen
SeqCap v2.0, and the percentage of reads mapping to the
reference was 94.2% (Agilent) and 75.3% (NimbleGen).
Table 2 presents the sequencing and mapping statistics for
individual lanes as well as the mean sequencing and map-
ping values from the 25 additional exome samples (see
Material and methods for details). The additional exome
samples were aligned only against the reference genome
and the capture target region (CTR) of the kit in question,
so only these numbers are shown. In general, sequencing
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144 369
Agilent SureSelect
157 523
CCDS v59
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1370
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1286
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17 685
(a)
NimbleGen SeqCap v2.0
188 119
CCDS v59
174 430
Agilent SureSelect 50Mb
205 568
9585
22 380
5683
172 166
685
1437
142
(b)
Figure 1 Comparison of the probe designs of the exome capture kits against CCDS exon annotations. (a, b) Given are the numbers of
CCDS exon regions, common target regions outside CCDS annotations and the regions covered individually by the Agilent SureSelect and
NimbleGen SeqCap sequence capture kits (a) and the Agilent SureSelect 50 Mb and NimbleGen SeqCap v2.0 sequence capture kits (b). Regions
of interest are defined as merged genomic positions regardless of their strandedness, which overlap with the kit in question. Sizes of the
spheres are proportional to the number of targeted regions in the kit. Total numbers of targeted regions are given under the name of each
sphere.
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Page 3 of 17reads from the NimbleGen exome capture kits had more
duplicated read pairs than the Agilent kits. On average,
14.7% of high quality reads were duplicated in Nimble-
Gen SeqCap versus 10.0% that were duplicated in Agilent
SureSelect (P > 0.05) and 23.3% were duplicated in Seq-
Cap v2.0 versus 7.3% that were duplicated in SureSelect
50 Mb (P = 0.002). However, the alignment of the
sequence reads to the CTR was more precise using the
NimbleGen kits and resulted in a greater amount of dee-
ply sequenced (≥ 20×) base pairs in the target regions of
interest. On average, 61.8% of high quality reads aligned
to the CTR and 78.8% of the CTR base pairs were cov-
ered with a minimum sequencing depth of 20× with
NimbleGen SeqCap versus 51.7% of reads that aligned to
the CTR and 69.4% of base pairs that were covered with
≥ 20× with Agilent SureSelect (P = 0.031 and P =5 . 7×
10
-4, respectively). For the updated kits, 54.0% of the
reads aligned to the CTR and 81.2% of base pairs cov-
ered with ≥ 20× with SeqCap v2.0 versus 45.1% of reads
that aligned to the CTR and 60.3% of base pairs that
were covered with ≥ 20× with SureSelect 50 Mb (P =
0.009 and P =5 . 1×1 0
-5, respectively).
Table 1 Capture probe designs of the compared exome capture kits
Exome
capture
method
Probes Base pairs
covered
(kb)
CCDS
exons
targeted
a
Complete CCDS
transcripts
targeted
b
miRNAs
targeted
c
Mean GC content of
the target regions
d
Percentage of
base pairs in
repeats
e
Percentage of
base pairs in
CNVs
f
Agilent
SureSelect
347 k 37,627 274,264 20,699 646 50.56% 0.2% 34.5%
Agilent
SureSelect
50 Mb
635 k 51,647 300,040 23,031 669 50.56% 0.8% 38.3%
NimbleGen
SeqCap
2.1 M 33,931 252,479 18,865 559 50.45% 1.3% 33.9%
NimbleGen
SeqCap v2.0
2.1 M 44,007 298,304 23,028 686 50.34% 2.1% 35.3%
aThere are 301,082 exons annotated in total in CCDS from Ensembl v59.
bAll CCDS annotated exons of a transcript are required to be included in the capture
target region. There are 23,634 transcripts in total in CCDS from Ensembl v59.
cThere are 712 miRNAs in total in miRBase v.15.
dThe mean GC content for all
CCDS annotated exon regions is 52.12%.
eRepeatMasker, April 2009 freeze.
fDatabase of Genomic Variants, March 2010 freeze. CNV, copy number variation; M,
million.
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Figure 2 Overview of the variant calling pipeline. VCP consists of sequence analysis software and in-house built algorithms, and its output
gives a wide variety of sequencing results. Sequence reads are first filtered for quality. Sequence alignment is then performed with BWA,
followed by duplicate removal, variant calling with SAMtools’ pileup and in-house developed algorithms for SNV calling with qualities and REA
calling. File transformation programs are used to convert different file formats between the software. White boxes, files and intermediate data;
purple boxes, filtering steps; grey ellipses, software and algorithms; green boxes, final VCP output; yellow boxes, files for data visualization; area
circled with blue dashed line, VCP analysis options not used in this study. PE, paired end.
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Page 4 of 17When mutations underlying monogenic disorders are
searched for with whole exome sequencing, every
missed exon causes a potential need for further PCR
and Sanger sequencing experiments. We thus wanted to
evaluate the exome capture kits’ capability to capture all
coding sequences of the human genome by assessing
how many complete CCDS transcripts (that is, having
captured all the annotated exons from the transcript)
the kits actually captured in the control I sample. The
number of complete transcripts captured with a mini-
mum coverage of 20× was 5,074 (24.5% of all targeted
complete transcripts in the CTR) for Agilent SureSelect,
4,407 (19.1% of targeted transcripts) for Agilent SureSe-
lect 50 Mb, 7,781 (41.3% of targeted transcripts) for
NimbleGen SeqCap and 9,818 (42.6% of targeted tran-
scripts) for NimbleGen SeqCap v2.0. The respective per-
centages of the captured, targeted individual exons were
65.8% (55.8% of all annotated exons), 62.0% (57.6%),
Table 2 Statistics of the sequencing lanes for the control I sample and mean values for the additional samples
Percentage of base pairs in the
target region covered ≥ 20×
b
Exome capture
method
Read
length
(bp)
Number
of high
quality
reads
a
Mb of
sequence
Percentage of
reads removed
in duplicate
removal
Percentage of
high quality
reads aligned to
hg19
Percentage of
high quality
reads aligned
to CTR
CTR CTR +
flank
CCDS Common
Agilent SureSelect
Lane 1 60 32,943,000 1,980 6.45% 90.27% 54.71% 45.31% 29.05% 42.04% 46.57%
Lane 2 82 57,259,000 4,700 9.24% 81.42% 51.50% 60.84% 46.87% 54.54% 61.82%
Combined 90,202,000 6,670 8.22% 84.65% 52.67% 68.15% 55.3% 60.98% 69.2%
Agilent SureSelect
50 Mb
Lane 1 82 41,871,000 3,430 5.23% 93.59% 42.96% 45.66% 33.62% 47.04% 44.71%
Lane 2 82 56,407,000 4,630 6.15% 92.37% 42.25% 53.72% 42.83% 54.54% 53.81%
Conditionally
combined
c
82 67,755,000 5,560 4.44% 94.15% 43.17% 60.25% 50.05% 60.95% 60.82%
NimbleGen
SeqCap
Lane 1 60 33,518,000 2,010 8.98% 90.79% 73.57% 56.96% 38.24% 44.78% 59.18%
Lane 2 82 62,141,000 5,100 14.92% 84.42% 71.27% 75.41% 57.52% 59.69% 77.1%
Combined 95,659,000 7,110 12.84% 86.65% 72.08% 82.33% 66.65% 65.45% 83.74%
NimbleGen
SeqCap v2.0
Lane 1 82
d 85,072,000 6,980 24.48% 75.27% 51.22% 79.99% 70.84% 77.55% 81.1%
Mean for the
additional
samples
e
Agilent
SureSelect (n
=2 )
82 71,201,000 5,840 10.37% 88.72% 51.84% 73.63% - - -
Agilent
SureSelect 50
Mb (n =2 )
82 67,089,000 5,500 8.65% 90.41% 46.03% 60.30% - - -
NimbleGen
SeqCap (n =
19)
82 67,626,000 5,550 14.66% 81.98% 61.25% 78.94% - - -
NimbleGen
SeqCap v2.0
(n =2 )
82
f 70,638,000 5,790 22.76% 76.97% 55.35% 81.82% - - -
aNumber of reads after B block trimming.
bTarget region abbreviations: CTR, own capture target region of the kit; CTR + flank, own capture target region ± 100
bp; CCDS, exon annotated regions from CCDS, Ensembl v59; Common, regions captured by all the kits in comparison.
cData from the sequencing lanes combined
and randomly down-sampled to meet comparable read amounts after filtering.
dSequenced with 100 bp, reads trimmed to 82 bp prior to any other action.
eThe
additional exome samples were aligned only against the whole genome and own capture target region.
fSequenced with 110 bp, reads trimmed to 82 bp prior
to any other action.
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Page 5 of 1783.4% (65.1%) and 85.3% (78.7%). Figure 3 shows the
numbers of complete transcripts captured with each
exome capture method with different minimum mean
thresholds. Individual CCDS exons targeted by the
methods and their capture successes in the control I
sample are given in Additional files 2 to 5.
We examined in detail the target regions that had
poor capture success in the control I sample. GC con-
tent and mapability were determined for the regions in
each method’s CTR, and the mean values were com-
pared between regions with mean sequencing depths of
0×, < 10×, ≥ 10× and ≥ 20×. High GC content was
found to be associated with poor capture success in all
exome enrichment methods. Table 3 shows the mean
GC content for targets divided in groups according to
mean sequencing coverage. We found no correlation
with the sequencing depth and mapability. To compare
poorly and well captured regions between the different
capture kits, GC content and mapability were deter-
mined for the common regions that were equally tar-
geted for capture in all kits. Regions with poor capture
success in one method (0×) and reasonable capture suc-
cess in another method (≥ 10×) were then analyzed
(Additional file 6). Similarlyt ot h eC C D Sr e g i o n s ,t h e
Agilent platforms captured less of the common target
regions in total. The regions with poor coverage in the
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Figure 3 Number of fully covered CCDS transcripts with different minimum coverage thresholds. For each exon, median coverage was
calculated as the sum of sequencing coverage on every nucleotide in the exon divided by the length of the exon. If all the annotated exons of
a transcript had a median coverage above a given threshold, the transcript was considered to be completely covered. The number of all CCDS
transcripts is 23,634.
Table 3 GC content of the target regions covered with
different sequencing depths
Mean sequencing coverage of targets
Exome capture method 0× < 10× ≥ 10× ≥ 20×
Agilent SureSelect 69.00% 64.78% 46.45% 44.52%
Agilent SureSelect 50 Mb 66.39% 65.03% 47.23% 45.01%
NimbleGen SeqCap 69.09% 68.56% 48.54% 47.00%
NimbleGen SeqCap v2.0 68.46% 70.15% 48.89% 47.50%
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Page 6 of 17Agilent kits and reasonable coverage in the NimbleGen
kits had a higher GC content than the common target
regions on average (65.35% in the smaller kits and
66.93% in the updated kits versus mean GC content of
50.71%). These regions also had a higher GC content
than the regions that were captured poorly by Nimble-
Gen and reasonably well by Agilent (the GC content in
the regions was, respectively, 65.35% versus 59.83% for
the smaller kits, and 66.93% versus 62.51% for the
updated kits). The regions with poor coverage with
NimbleGen and reasonable coverage with Agilent had
minutely lower mapability (0.879 versus 0.995 for the
smaller kits, and 0.981 versus 0.990 for the updated
kits). Both vendors’ updated kits performed better in the
regions with high GC content or low mapability than
the smaller kits.
SNVs and SNPs
SNVs were called using SAMtools’ pileup [13]. In addi-
tion to pileup genotype calls, an in-house developed
algorithm implemented in the VCP was used to re-call
these genotypes. The VCP algorithm takes advantage of
allele quality ratios of bases in the variant position (see
the ‘Computational methods’ section). Genome-wide, we
found 26,878 ≥ 20× covered SNVs with Agilent SureSe-
lect, 42,799 with Agilent SureSelect 50 Mb, 25,983 with
NimbleGen SeqCap and 56,063 with NimbleGen SeqCap
v2.0 with approximately 58 million 82-bp high-quality
reads in the control I sample. In the additional 25 sam-
ples the numbers of found variants were higher for the
small exome capture kits than in the control I sample:
genome-wide, 42,542, 43,034, 33,893 and 50,881 SNVs
with a minimum coverage of 20× were found on average
with 59 million reads, respectively. Figure 4 shows the
number of novel and known SNVs identified in the
CTR and CCDS regions for the control I sample and
the mean number of novel and known SNVs in the
CTR for the additional samples. The mean allele bal-
ances for the heterozygous variants were examined gen-
ome-wide and within the CTRs for the control I sample
as well as for the additional samples. Interestingly, het-
erozygous SNVs within the CTRs showed higher allele
ratios, indicating a tendency to have more reference
bases than variant bases in the variant positions, while
the allele balances of the SNVs mapping outside the
CTRs were more equal (Table 4). Moreover, allele bal-
ances tended to deviate more from the ideal 0.5 towards
the reference call with increasing sequencing depth
(Additional file 7).
We next estimated the proportion of variation that
each capture method was able to capture from a single
exome. This was done by calculating the number of
SNVs identified by each kit in the part of the target
region that was common to all kits in the control I
sample. As this region was equally targeted for sequence
capture in all exome kits, ideally all variants from the
region should have been found with all the kits. Alto-
gether, 15,044 quality filtered SNVs were found in the
common target region with a minimum coverage of
20×. Of these SNVs, 8,999 (59.8%) were found with Agi-
lent SureSelect, 9,651 (64.2%) with SureSelect 50 Mb,
11,021 (73.3%) with NimbleGen SeqCap and 13,259
(88.1%) with SeqCap v2.0. Sharing of SNVs between the
kits is presented in Figure 5. Of the 15,044 variant posi-
tions identified with any method in the common target
region, 7,931 were covered with a minimum of 20× cov-
erage by all four methods, and 7,574 (95.5%) of them
had the same genotype across all four methods. Most of
the remaining 357 SNVs with discrepant genotypes had
an allele quality ratio close to either 0.2 or 0.8, position-
ing them in the ‘grey zone’ between the clear genotype
clusters, thus implying an accidental designation as the
wrong genotype class. For the majority of the SNVs (n
= 281) only one of the capture methods disagreed on
the genotype, and the disagreements were randomly dis-
tributed among the methods. Agilent SureSelect had 51,
SureSelect 50 Mb 87, NimbleGen SeqCap 98 and Seq-
Cap v2.0 45 disagreeing genotypes.
In order to assess the accuracy of the identified var-
iants, we compared the sequenced genotypes with geno-
types from an Illumina Human660W-Quad v1 SNP chip
for the control I sample. From the SNPs represented on
the chip and mapping to a unique position in the refer-
ence genome, 11,033 fell inside the Agilent SureSelect
CTR, 14,286 inside the SureSelect 50 Mb CTR, 9,961
inside the NimbleGen SeqCap CTR and 12,562 inside
the SeqCap v2.0 CTR. Of these SNPs, Agilent SureSelect
captured 6,855 (59.7%) with a minimum sequencing
coverage of 20×, SureSelect 50 Mb captured 8,495
(59.5%), NimbleGen SeqCap captured 7,436 (74.7%) and
SeqCap v2.0 captured 9,961 (79.3%). The correlations of
sequenced genotypes and chip genotypes were 99.92%,
99.94%, 99.89% and 99.95%, respectively. The number of
concordant and discordant SNPs and genotype correla-
tions for lower sequencing depths are shown in Table 5.
We further examined the correlation separately for
reference homozygous, variant homozygous and hetero-
zygous SNP calls based on the chip genotype. The cause
of most of the discrepancies between the chip and
sequenced genotype turned out to be heterozygous chip
genotypes that were called homozygous reference bases
in the sequencing data, though the number of differing
SNPs was too small to make any definite conclusions.
Forty-seven of the discordant SNPs were shared
between all four exome capture methods with a reason-
ably deep (≥ 10×) sequencing coverage for SNP calling.
Only two of these SNPs had the same VCP genotype
call in all four methods, indicating probable genotyping
Sulonen et al. Genome Biology 2011, 12:R94
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Page 7 of 17errors on the chip. One SNP was discordant in two
methods (Agilent SureSelect and NimbleGen SeqCap),
and the rest of the discordant SNPs were discordant in
only one method, suggesting incorrect genotype in the
sequencing: 12 SNPs in Agilent SureSelect, 26 in Sure-
Select 50 Mb and 6 in NimbleGen SeqCap. Figure 6
shows the genotype correlation with different minimum
sequencing coverages. Additional file 8 presents the cor-
relations between the sequenced genotype calls and chip
genotypes with the exact sequencing coverages. Reasons
for differences between the methods in the genotype
correlation with the lower sequencing depths were
examined by determining GC content and mapability
f o rt h er e g i o n sn e a rt h ed i s c o r d a n tS N P s .A se x p e c t e d ,
GC content was high for the SNPs with low sequencing
coverage. Yet there was no difference in the GC content
between concordant and discordant SNPs. Additionally,
we did not observe any remarkable difference in the GC
content of concordant and discordant SNPs between the
different capture methods, independent of sequencing
coverage (data not shown). Mapabilities for all the
regions adjacent to the discordant SNPs were 1.0; thus,
they did not explain the differences. Despite the allele
balances for the heterozygous variants being closer to
the ideal 0.5 outside the CTRs than within the CTRs,
there was no notable improvement in the genotype cor-
relation when examining SNPs in the regions with more
untargeted base pairs (data not shown).
Correlations between the original SAMtools’ pileup
[13] genotypes and the chip genotypes, as well as
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were filtered based on the allele quality ratio in VCP. Numbers are given for variants with a minimum sequencing depth of 20× in the capture
target region (CTR) and CCDS annotated exon regions (CCDS) for the control I sample. Mean numbers for the variants found in the CTRs of the
additional samples are also given (CTR Mean). Dark grey bars represent Agilent SureSelect (left panel) and SureSelect 50 Mb (right panel); black
bars represent NimbleGen SeqCap (left panel) and SeqCap v2.0 (right panel); light grey bars represent novel SNPs (according to dbSNP b130).
Table 4 Mean allele balances of heterozygous SNVs genome-wide and in CTRs
Control I Additional samples
Exome capture method Number of samples Genome-wide
a CTR
b Genome-wide
a CTR
b Student’s t-test P
c
Agilent SureSelect 3 0.517 0.524 0.511 0.517 0.007
Agilent SureSelect 50 Mb 3 0.515 0.520 0.514 0.519 0.003
NimbleGen SeqCap 20 0.516 0.527 0.514 0.523 7.1 × 10
-15
NimbleGen SeqCap v2.0 3 0.512 0.518 0.514 0.519 0.013
aAll called heterozygous SNVs with minimum sequencing coverage of 20×, regardless of target region.
bHeterozygous SNVs with minimum sequencing coverage
of 20× called within the CTRs.
cStudent’s t-test P-value for the difference between CTR and all sequenced regions given for the combined sample set of the
control I sample and 25 additional samples.
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lysis Toolkit (GATK) [18], were also examined and are
given in Additional file 9. Recalling of the SNPs with
quality ratios in the VCP greatly enhanced the genotype
correlation of heterozygous SNPs from that of the origi-
nal SAMtools’ pileup genotype correlation. For the het-
erozygous SNPs, GATK genotypes correlated with the
chip genotypes slightly better than the VCP genotypes
with low sequencing coverages (5× to 15×), especially
for the smaller versions of the capture kits. However,
correlation of the variant homozygous SNPs was less
accurate when GATK was used.
Insertion-deletions
Small indels variations were called with SAMtools
pileup for the control I sample. Altogether, 354 inser-
tions and 413 deletions were found in the CTR of Agi-
lent SureSelect, 698 insertions and 751 deletions in the
CTR of SureSelect 50 Mb, 365 insertions and 422 dele-
tions in the CTR of NimbleGen SeqCap and 701 inser-
tions and 755 deletions in the CTR of SeqCap v2.0, with
the minimum sequencing coverage of 20×. The size of
the identified indels varied from 1 to 34 bp. There was
practically no difference in the mean size of the indels
between the capture methods. Of all 2,596 indel posi-
tions identified with any one of the methods, 241 were
identified by all four methods, 492 by any three methods
and 1,130 by any two methods; 119 were identified only
with Agilent SureSelect, 619 only with SureSelect 50
Mb, 149 only with NimbleGen SeqCap and 579 only
with SeqCap v2.0. We further attempted to enhance the
identification of indels by searching for positions in the
aligned sequence data where a sufficient number of
overlapping reads had the same start or end position
without being PCR duplicates (see the ‘Computational
methods’ section). These positions were named as REAs.
NimbleGen SeqCap v2.0
NimbleGen SeqCap
Agilent SureSelect 
50Mb
Agilent SureSelect
7931
(7574)
55
110
593
1158
65
(64)
266
(254)
48
(45)
2038
(1980)
Figure 5 Sharing of single nucleotide variants between the exome capture kits. The number of all sequenced variants in the common
target region was specified as the combination of all variants found with a minimum coverage of 20× in any of the exome capture kits
(altogether, 15,044 variants). Variable positions were then examined for sharing between all kits, both Agilent kits, both NimbleGen kits, Agilent
SureSelect kit and NimbleGen SeqCap kit, and Agilent SureSelect 50 Mb kit and NimbleGen SeqCap v2.0 kit. Numbers for the shared variants
between the kits in question are given, followed by the number of shared variants with the same genotype calls. The diagram is schematic, as
the sharing between Agilent SureSelect and NimbleGen SeqCap v2.0, Agilent SureSelect 50 Mb and NimbleGen SeqCap or any of the
combinations of three exome capture kits is not illustrated.
Table 5 Genotype correlations with the genome-wide SNP genotyping chip for lower sequencing coverages
Sequencing depth 1× to 5× Sequencing depth 6× to 10× Sequencing depth 11× to 15×
Exome
capture
method
Number of
concordant
SNPs
Number of
discordant
SNPs
Genotype
correlation
Number of
concordant
SNPs
Number of
discordant
SNPs
Genotype
correlation
Number of
concordant
SNPs
Number of
discordant
SNPs
Genotype
correlation
Agilent
SureSelect
779 258 75.12% 802 46 94.58% 647 17 97.44%
Agilent
SureSelect
50 Mb
846 243 77.69% 1,127 37 96.82% 1,109 14 98.75%
NimbleGen
SeqCap
206 60 77.44% 361 19 95.00% 459 13 97.25%
NimbleGen
SeqCap v2.0
110 39 73.83% 338 9 97.41% 486 3 99.39%
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Figure 6 Correlation of sequenced genotypes to the SNP chip genotypes. SAMtools’ pileup genotype calls recalled with quality ratios in
the VCP were compared with the Illumina Human660W-Quad v1 SNP chip genotypes. (a) The correlations for Agilent SureSelect- and
NimbleGen SeqCap-captured sequenced genotypes. (b) The correlations for SureSelect 50 Mb- and SeqCap v2.0-captured sequenced genotypes.
Correlations for heterozygous, reference homozygous and variant homozygous SNPs (according to the chip genotype call) are presented on
separate lines, though the lines for homozygous variants, laying near 100% correlation, cannot be visualized. The x-axis represents the
accumulative minimum coverage of the sequenced SNPs.
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157 in the CTR of SureSelect 50 Mb, 53 in the CTR of
NimbleGen SeqCap and 92 in the CTR of SeqCap v2.0.
Only four of these REAs were found with all four meth-
ods, despite 110 of them being in the common region
targeted for capture in all. Agilent’s capture methods
shared 27 REAs and NimbleGen’s methods shared 19
REAs. Of the indels identified with pileup, 30% over-
lapped with known indels from dbSNP b130 and 43% of
the REAs overlapped with a known copy number varia-
tion (Database of Genomic Variants, March 2010
freeze). Extensive validation of the found indels is
needed for the evaluation of the algorithms.
Simulation of exome sequencing in monogenic diseases
Finally, we evaluated the exome capture kits’ potential in
finding a set of disease-causing mutations of monogenic
disorders. Using 48 previously published mutation loci
of 31 clinically relevant disorders of the Finnish disease
heritage (references are giveni nt h eA d d i t i o n a lf i l e1 0 )
as an example, we examined whether the methods had
successfully and reliably captured these genomic posi-
tions in the control I sample. With a minimum coverage
of 10×, Agilent SureSelect captured 34 of the mutation
loci, SureSelect 50 Mb captured 34, NimbleGen SeqCap
39 and SeqCap v2.0 captured 42 of the mutation loci.
When the threshold was raised to ≥ 20× coverage, the
kits captured 30, 30, 34 and 37 disease-causing mutation
loci, respectively. Four loci were missed by all the kits
despite the loci being within the CTR of each kit. Of
note, no mutant alleles were found in any of the covered
loci for the control I sample. Additional file 10 shows
the examined diseases, genomic positions of the muta-
tions, mutation types and the sequencing coverage of
different exome capture kits on the loci.
Discussion
Our results show more specific targeting and enrich-
ment characteristics for sequencing libraries captured
with the Roche NimbleGen exome capture kits than for
libraries captured with the Agilent kits. Although
sequences of the libraries prepared using the Agilent
kits had less duplicated reads and their aligning to the
human reference genome was equal to that of the Nim-
bleGen kits, the latter had more high quality reads and
deeply covered base pairs in the regions actually tar-
geted for sequence capture. The alignment results indi-
cate a more widespread distribution of the sequencing
reads from Agilent kits within the genome.
High GC content of the target regions correlated with
low sequencing coverage in all exome capture methods.
The GC content seemed to affect Agilent’sl o n gR N A -
based probes slightly more than NimbleGen’sD N A -
based probes, but it did not solely explain the difference
in capture success between the methods. Carefully
balanced probe design with shorter and more numerous
probes in NimbleGen’sk i t ss e e m e dt op r o v i d eam o r e
uniform coverage throughout the target regions, includ-
ing the challenging areas.
Evaluation of the allele balances of the identified het-
erozygous SNVs revealed no major differences between
the NimbleGen and Agilent capture methods. However,
we observed that the variations outside the CTRs had a
more ideal balance, close to 0.5, than the heterozygous
variations in the CTRs. This was true for both exome
capture method vendors. This suggests that the capture
probes, being specific for the reference sequence, favor
the reference alleles in the hybridization and capture
processes. SNVs identified outside the CTRs are cap-
tured because of the overflow of sequencing fragments
beyond the targeted regions, and thus are not under the
selection of an annealing probe. Furthermore, deviation
from 0.5 increased with increasing sequencing depth.
Both vendors slightly improved their allele balances in
their updated capture kits.
SNP correlation with the Illumina Human660W-Quad
v1 SNP chip was not notably different between the
exome capture methods. All methods captured the
SNPs with a high correlation of more than 99.7% when
a minimum sequencing depth of 20× was used. When
the allele quality ratios were considered in the SNP call-
ing, over 99% correlation with common SNPs repre-
sented on the genotyping chip was already achieved
with an approximate minimum sequencing depth of
10×. However, common SNPs on genome-wide associa-
tion arrays are biased towards easy-to-genotype SNPs,
and novel variants likely need a deeper sequencing cov-
erage for an accurate genotype.
The number of captured CCDS exons and transcripts
and found SNVs closely followed the success rate of the
short read alignment in the region of interest. This was
also seen with indel variations and how the methods
captured the previously identified mutation loci of the
Finnish disease heritage. As all the following sequence
analysis steps were dependent on the sequencing depth,
deep and uniform sequencing coverage of the CTR is
essential for the sequence capture method’sp e r f o r -
mance. This makes the normalization of read counts a
crucial step for a systematic comparison. We chose to
use comparable amounts of effective reads (that is, high
quality, not duplicated reads) in the read alignment. The
possible effect the different sample preparation methods
had on the need for sequencing read trimming and
duplicate removal was potentially minimized with this
approach, and allowed us to carry out the comparison
chiefly on the kits’ target enrichment characteristics.
Teer et al. [19] used the number of filtered reads in
the normalization of their data in a comparison of
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microarray-based capture and molecular inversion probe
capture of custom non-contiguous targets, exons and
conserved regions. According to their results, Nimble-
Gen microarray-based capture was the most sensitive
method. On the other hand, Kiialainen et al. [20] came
to a different conclusion in their comparison of Agilent
SureSelect custom capture and Roche NimbleGen
microarray capture methods targeted at 56 genes,
including exons, introns and sequences upstream and
downstream of the genes. More sequencing reads from
their Agilent captures aligned to the CTR compared to
their NimbleGen captures. The regions targeted for cap-
ture were rather different in these two comparisons, the
region in Teer et al. possibly resembling more the
whole exome target. This suggests that capture probe
design with shorter probes of flexible length might be
more easily applied to non-contiguous targets. However,
Mamanova et al. [21] stated in their review on sequence
capture methods that no appreciable differences were
noticed between the performances of Agilent SureSelect
and NimbleGen SeqCap solution-based methods.
We made some modifications to the protocols pro-
vided by the vendors for equalization purposes. It can
be hypothesized that these modifications could have
altered the balance of target DNA and the capture
probes in the hybridization, and by this mechanism the
subsequent alignment of short reads into the CTRs.
Moreover, Fisher et al. [22] showed in their study on
automation of the Agilent SureSelect sequence capture
procedure that the mapping sensitivity and specificity of
the kit can be improved with extensive optimization.
Only one of our samples was captured with all four
exome capture methods. Although we observed some
sample-specific variation in the 25 samples captured
with only one method, the mean values across these
additional samples were consistent with the values of
the control I sample. The observed differences in the
number of duplicated reads, the number of reads map-
ping to the CTR and the percentage of the CTR covered
by at least 20 reads between Agilent SureSelect and
NimbleGen SeqCap kits were statistically significant.
Conclusions
When their limitations are acknowledged, whole exome
sequence capture kits are an efficient method to target
next-generation sequencing experiments on the best
understood regions of the genome. One obvious limita-
tion is that none of the capture kits were able to cover
all the exons of the CCDS annotation, although there
has been improvement in this in the updated versions of
the kits. An additional shortage is the lack of targeting
of the 5’ and 3’ untranslated regions, especially in stu-
dies of complex diseases, in which protein coding
sequences are not necessarily expected to be altered.
We found no major differences in the performance of
the kits regarding their ability to capture variations
accurately. In our data, libraries captured with Nimble-
Gen kits aligned more accurately to the target regions.
NimbleGen Seqcap v2.0 most efficiently covered the
exome with a minimum coverage of 20×, when compar-
able amounts of sequence reads were produced from all
four capture libraries.
Materials and methods
Samples
The control I sample was an from anonymous blood
donor. The DNA was extracted from the peripheral
blood using a standard method based on salt precipita-
tion at the Public Health Genomics, National Institute
for Health and Welfare, Helsinki, Finland. In addition,
we estimated the performance of different exome cap-
ture methods by auditing the quality and quantity of
exome sequencing data produced for purposes of five
on-going research projects employing the herein
described core-facility services. Each research project
was approved by an Ethics Committee (Ethics Commit-
tees of the Helsinki University Central Hospital and
Bioethics Committee of the Institute of Oncology, Maria
Sklodowska-Curie, Warsaw). All samples were taken in
accordance with the Helsinki Declaration, with oral or
written consent from the patients or their parents. All
samples were processed anonymously, and the samples
were prepared and analyzed in our core-facility labora-
tory using the same protocols. This auditing allowed us
to compare the overall performance of different exome
capture methods, and to monitor the quality of the
sequence data. Two of the additional samples were pre-
pared and captured with the Agilent SureSelect Human
All Exon kit, two with the Agilent SureSelect Human
All Exon 50 Mb kit, 19 with the NimbleGen SeqCap EZ
Exome kit and two with the NimblGen SeqCap EZ
Exome v2.0 kit. DNA was extracted from the samples in
the respective laboratory responsible for each research
project using standard protocols.
Sample preparation I
For sample preparation I (control I sample, Additional
file 11a), two sets of 3 μg of DNA were fragmented with
a Covaris S-2 instrument (Covaris, Woburn, MA, USA),
purified with QIAquick PCR purification columns (Qia-
gen, Hilden, Germany) and pooled together. Fragmenta-
tion success was verified by running 4 μlo ft h es a m p l e
on a FlashGel (Lonza, Allendale, NJ, USA). The rest of
the sample was divided, and the end repairing, A-tailing
and adapter ligation and the concomitant column purifi-
cations were done in parallel for the divided sample
with NEBNext DNA Sample Prep Master Mix Set 1
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concentrations recommended by the manufacturer and
the Qiagen purification columns. For the adapter liga-
tion, adapters were formed from primers 5’-GATCG-
GAAGAGCGGTTCAGCAGGAATGCCGAG-3’and 5’-
ACACTCTTTCCCTACACGACGCTCTTCCGATCT-3’
(oligonucleotide sequences
© 2006-2008 Illumina, Inc.,
Allendale, NJ, USA, all rights reserved) by mixing 5
nmol of both primers, heating to 96°C for 2 minutes
and cooling down to room temperature. Twenty-five
pmol of the adapter was used for the ligation reaction.
After completion of sample preparation, the samples
were first pooled and then split to ascertain a uniform
starting product for both sequence capture methods.
For the NimbleGen SeqCap EZ Exome capture (later
referred to as NimbleGen SeqCap; Roche NimbleGen,
Madison, WI, USA), the adapter-ligated sample was run
on a 2% TBE-agarose gel, following which a gel slice con-
taining 200 to 300 bp of DNA was extracted, purified with
a QIAquick Gel Extraction column (Qiagen) and analyzed
on a Bioanalyzer High Sensitivity DNA chip (Agilent,
Santa Clara, CA, USA). Twenty nanograms of the sample
was mixed with 25 μl of 2× Phusion HF PCR Master Mix
(Finnzymes, Espoo, Finland), 1.2 μlo f2 0μM forward and
reverse PE PCR primers (5’-AATGATACGGCGAC
CACCGAGATCTACACTCTTTCCCTACACGACGC
TCTTCCGATCT-3’ and 5’-CAAGCAGAAGACGGCA
TACGAGATCGGTCTCGGCATTCCTGCTGAACCGC
TCTTCCGATCT-3’ (oligonucleotide sequences
© 2006-
2008 Illumina, Inc., all rights reserved). ddH2O was added
to reach the final reaction volume of 50 μlt ob eu s e df o r
four parallel reactions in the pre-capture PCR. The cycling
conditions were as follows: initial denaturation at 98°C for
2 minutes; 8 cycles of 98°C for 20 seconds, 65°C for 30
seconds and 72°C for 30 seconds; final extension at 72°C
for 5 minutes, and cooling down to 10°C until further use.
The PCR products were pooled together, purified with a
QIAquick PCR purification column and analyzed on a
Bioanalyzer DNA1000 chip (Agilent). One microgram of
the product was prepared for hybridization with the cap-
ture oligomeres; the hybridization was carried out at 47°C
for 70 hours and the product was captured using Strepta-
vidin M-270 Dynabeads (Invitrogen, Carlsbad, CA, USA)
according to the NimbleGen SeqCap protocol.
For the Agilent SureSelect Human All Exon capture
(later referred to as Agilent SureSelect), the adapter-
ligated sample was purified using Agencourt AMPure
XP beads (Beckman Coulter, Brea, CA, USA) and ana-
lyzed on a Bioanalyzer High Sensitivity DNA chip.
Twenty nanograms of the sample was used for pre-cap-
ture PCR in four parallel reactions in the same condi-
tions as for the NimbleGen SeqCap. The PCR products
were pooled together, purified with a QIAquick PCR
purification column and analyzed on a Bioanalyzer
DNA1000 chip. Five-hundred nanograms of the sample
was prepared for the hybridization with the capture
baits, and the sample was hybridized for 24 hours at 65°
C, captured with the Streptavidin M-280 Dynabeads and
purified using a Qiagen MinElute column according to
the manufacturer’s protocol.
After hybridization and capturing the DNA with strep-
tavidin beads, the captured yield was measured using
quantitative PCR. A standard curve was created using a
previously prepared Illumina GAIIx sequencing sample
with known concentrations of DNA ranging from 0.3
pg/μl to 21.5 pg/μl. One microliter of both capture sam-
ple and each control sample solutions were used in tri-
plicate PCR reactions, performed with a DyNAmo HS
SYBRGreen qPCR kit (Finnzymes) and PCR primers
specific for the PE sequencing primer tails (5’-
ATACGGCGACCACCGAGAT-3’ and 5’-AGCAGAA-
GACGGCATACGAG-3’), and run on a LightCycler
®
480 Real-Time PCR system (Roche NimbleGen). The
original DNA concentrations of the capture samples
were calculated from the standard curve; 246 pg of
DNA was captured with the Agilent SureSelect baits
and 59 pg with the NimbleGen SeqCap probes.
After finding out the DNA concentrations of the cap-
tured samples, the PCR conditions were optimized for
the post-capture PCR-reactions. The most comparable
libraries, defined as uniform library sizes and equivalent
yields, were obtained by using 5 pg of the captured sam-
ple and 14 cycles of PCR for the NimbleGen SeqCap
and 10 pg of the captured sample and 16 cycles of PCR
for the Agilent SureSelect. Stratagene Herculase II
enzyme (Agilent) was used for both PCRs. For the Nim-
bleGen SeqCap, primers 5’-AATGATACGGCGAC-
CACCGAGA-3’ and 5’-CAAGCAGAAGACGGCA
TACGAG-3’ were used at a concentration of 100 pmol.
For the Agilent SureSelect, a primer mix from the Sure-
Select kit was used as recommended by the manufac-
turer. Six parallel reactions were done for both of the
exome capture methods, the PCR products were purified
according to the exome kit protocols (AMPure SPRI-
beads for the Agilent SureSelect sample and QIAquick
PCR purification columns for the NimbleGen SeqCap
sample), following which the purified PCR products
were pooled and analyzed on a Bioanalyzer High Sensi-
tivity DNA chip. The samples were diluted to a concen-
t r a t i o no f1 0n M ,a n de q u a la m o u n t so ft h el i b r a r i e s
were run on an Illumina GAIIx sequencing instrument
according to the manufacturer’sp r o t o c o lu s i n gP E
sequencing.
Sample preparation II: exome kit updates
For sample preparation II (Additional file 11b), we
introduced 6 μg of control I DNA for fragmentation in
two batches. After fragmentation, the batches were
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both updated capture kits, as well as for the end repair,
adapter ligation and PCR steps, which were conducted
as described above. After each step the samples were
purified with Agencourt AMPure XP beads. One micro-
gramg of the sample library was hybridized with Roche
NimbleGen SeqCap EZ v2.0 probes and 500 ng of the
sample library with Agilent SureSelect Human All Exon
50 Mb baits. The hybridizations and captures were per-
formed according to the manufacturers’ updated proto-
cols. Quantitative PCR was performed as described in
the ‘Sample preparation I’ section. DNA (525 pg) was
captured with Agilent 50 Mb baits and 210 pg with
NimbleGen v2.0 baits. The post-capture steps were per-
formed as in the ‘Sample preparation I’ section.
Sequencing
Agilent SureSelect and NimbleGen SeqCap sequencing
libraries from sample preparation I were sequenced on
two lanes each; one lane with a read length of 60 bp
and another with 82 bp. As the recommended sequen-
cing length for all of the exome capture kits was 75 bp
at the minimum, only the data from the second sequen-
cing lanes of Agilent SureSelect and NimbleGen SeqCap
sequencing libraries were used in the analyses proceed-
ing from the alignment of individual lanes. Sequencing
libraries captured with the Agilent SureSelect 50 Mb
and NimbleGen SeqCap v2.0 kits during sample pre-
paration II were first sequenced on a single lane each.
As this resulted in incomparable read amounts (only 42
million reads were produced by the Agilent SureSelect
50 Mb, whereas 85 million reads were obtained from
the NimbleGen SeqCap v2.0), another sequencing lane
was produced for the SureSelect 50 Mb. Data from the
two Agilent SureSelect 50 Mb kit sequencing lanes were
combined, and the sequencing reads were randomly
down-sampled to meet comparable read amounts after
the trimming of B blocks from the read ends and the
removal of PCR duplicates. Both lanes for SureSelect 50
Mb were produced with a sequencing length of 82 bp.
The NimbleGen SeqCap v2.0 capture library was
sequenced with a read length of 100 bp and the reads
were trimmed to 82 bp prior to any other action. All
raw sequence data can be obtained from the Sequence
Read Archive (SRA) with study accession number [SRA:
ERP000788] [23].
SNP-chip
In order to evaluate the exome capture methods’ ability
to genotype common SNPs, the control I sample was
genotyped on an Illumina Human660W-Quad v1 SNP
chip in the Technology Centre of the Institute for Mole-
cular Medicine, Finland, according to the manufacturer’s
protocol. Genotypes were called using GenomeStudio
v2009.2. SNPs with < 95% genotyping success rate were
excluded from further analyses. To enable comparison
of the chip and sequenced genotypes, all flanking
sequences of the chip SNPs (provided by the manufac-
turer) were first aligned with Exonerate software [24]
against the human genome build hg19 (GRCh37). Geno-
types of the SNPs with a flanking sequence mapping to
the minus strand were then reversed to their reverse
complements. SNPs with multiple blasting results or no
results at all (n = 10 047) were removed from further
analyses.
Computational methods
Human genome build hg19 (GRCh37) Primary Assembly
(not including the unplaced scaffolds) was used as the
reference sequence throughout the analyses. Both Agilent
and NimbleGen have used exon annotations from the
CCDS and miRNA annotations from the miRBase based
on human genome build hg18 as the basis for their cap-
ture designs in the smaller kits. In the probe designs for
the larger kits, Agilent has used the CCDS (March 2009),
GENCODE, RefSeq, Rfam and miRBase v.13 annotations
based on human genome hg19, whereas the NimbleGen
SeqCap v2.0 design relies on the CCDS (September
2009), RefSeq (UCSC, January 2010), and miRBase (v.14,
September 2009) annotations, as well as on additional
genes from customer inputs. The updated kits included
capture probes for unplaced chromosomal positions as
well (namely, 378 probe regions in Agilent SureSelect 50
Mb and 99 in NimbleGen SeqCap v2.0), but these
regions were removed from our further analyses. CTRs
were defined for all of the capture kits as the companies’
given probe positions. These needed to be lifted over
from the given hg18 build positions to the recent hg19
positions for the smaller kits, whereas the updated kits’
designs had already been made using the hg19 build. In
some of our statistics (see Results), we included the
flanking 100 bp near all the given probe positions into
the CTRs (CTR + flank). Exon annotations from the
CCDS project build v59 (EnsEMBL) were used [10]. A
common target region for the capture methods was
defined as the probe regions that were included in all of
the probe designs.
For the probe design comparisons (Figure 1; Addi-
tional file 1), the exon regions of interest were defined
by combining CCDS and UCSC known exon [11] anno-
tated regions as well as all the kits’ capture target
regions into a single query. Overlapping genomic
regions were merged as single positions in the query.
For any given kit, an exon region was considered to be
included in the kit if its capture probe positions over-
lapped with the combined query for one base pair or
more. The numbers of included exon regions are given
in the figures.
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developed SAMtools-based bioinformatics pipeline for
quality control, short read alignment, variant identifica-
tion and annotation (VCP; Figure 2). Image analyses and
base calling of the raw sequencing data were first per-
formed on the Illumina RTA v1.6.32.0 sequence analysis
pipeline. In the VCP, the sequences were then trimmed
of any possible B block in the quality scores from the
end of the read. After this, if any pair had a read shorter
than 36 bp, the pair was removed. The quality scores
were converted to Sanger Phred scores using Emboss
(version 6.3.1) [25] and aligned using BWA (version
0.5.8 c) [12] against human genome build hg19. The
genome was downloaded from EnsEMBL (version 59).
After alignment, potential PCR duplicates were removed
with Picard MarkDuplicates (version 1.32).
SNVs were called with SAMtools’ pileup (version
0.1.8) [13]. The pileup results were first filtered by
requiring the variant allele quality to be 20 or more and
then with the SAMtools’ VarFilter. We calculated qual-
ity ratios for the variants as a ratio of A/(A + B), where
A and B were defined as follows: if there were call bases
of both the reference base and variant base in the var-
iant position, A was the sum of allele qualities of the
reference call bases and B was the sum of allele qualities
of the variant call bases; if there were two different var-
iant call bases and no reference call bases, the variant
call base with a higher allele quality sum was the A and
the other call base was the B; if all the call bases in the
variant position were variant calls of the same base, the
quality ratio was defined to be 0. In variant positions
with call bases of more than two alleles the ratio was
defined to be -1, and they were filtered from subsequent
analyses. Finally, single nucleotide variants called by
pileup were filtered in the VCP according to the
described quality ratio: any variant call with a quality
ratio of more than 0.8 was considered as a reference call
and was filtered out. In addition, we included our own
base calls for the called variants based on the quality
ratio. Any call with a quality ratio between 0.2 and 0.8
was considered to be heterozygous and calls below 0.2
to be homozygous variant calls.
For the control I sample, GATK base quality score
recalibration and genotype calling was done with recom-
mended parameter settings for whole exome sequencing
[18]. Known variants for quality score recalibration were
from the 1000 Genomes Project (phase 1 consensus
SNPs, May 2011 data release).
In addition to SNVs, small indels were called for the
control I sample using SAMtools’ pileup as well. The
results were filtered by requiring the quality to be 50 or
more and then with the SAMtools’ VarFilter. No other
alleles than the indel or reference allele calls were
allowed for the indel variant positions.
We hypothesized that indel, inversion or translocation
break points could be identified from the aligned
sequence data by examining genomic positions, where a
sufficient number of overlapping reads had the same
start or end position without being PCR duplicates.
Such positions could be caused by soft-clipping of reads
done by BWA: if only the start of a read aligned to the
reference sequence, but the rest of the read did not
align adjacently to it, BWA aligned only the start of the
read and reported a soft-clip from the un-aligned part.
Another possible cause for these positions was B blocks
in the quality scores, starting from the same position for
the overlapping reads, and subsequent B block trim-
ming. These positions were named as REAs. REAs were
searched for in the control I sample from the aligned
read file. At least five reads, all of them either starting
or ending in the same position, and a minimum contri-
bution of 30% to the total coverage in the position, were
required for a REA to be reported. Associated soft-
clipped sequences were reported together with REAs.
GC content was defined for the CTRs and the com-
mon target region as a mean percentage of G and C
bases in the targets, calculated from human genome
build hg19 (GRCh37) based FASTA formatted target
files with the Emboss geecee script [25]. For the SNP
analyses, GC content was defined as the percentage of
G and C bases in the distinct target (for example, a sin-
gle exon) adjacent to the SNP. Mapabilities were
retrieved from the UCSC Table Browser using track:
mapability, CRG Align 75 (wgEncodeCrgMapabilityA-
lign75mer). In this track, a mapability of 1.0 means one
match in the genome for k-mer sequences of 75 bp, 0.5
means two matches in the genome and so on. Mean
mapability was calculated for each distinct target region.
Similarly for the SNP analyses, mapability for a SNP was
defined as mean mapability in the region adjacent to the
SNP.
Student’s t-test was used to test for statistical signifi-
cance in the differences between the sequence alignment
results and between the SNV allele balances. T-distribu-
tion and equal variance were assumed for the results,
thought it should be noted that with a small number of
samples the results should be interpreted with caution.
Uncorrected two-tailed P-values are given in the text.
Additional material
Additional file 1: Comparison of the probe designs of the exome
capture kits against the CCDS exon annotation, UCSC exon
annotation and each other. (a) Numbers of CCDS exon regions,
common target regions outside CCDS annotations and the regions
covered individually by the Agilent SureSelect and Agilent SureSelect 50
Mb kits. SureSelect has one single region outside the SureSelect 50 Mb
design. (b) The same as (a) for the NimbleGen SeqCap and NimbleGen
SeqCap v2.0 kits. (c-f) The same as Figures 1a and 1b and Additional files
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Page 15 of 171a and 1b, respectively, but the exon annotation from UCSC is given
instead of the CCDS annotation. Regions of interest are defined as
merged genomic positions, regardless of their strandedness, which
overlap with the kit in question. Sizes of the spheres are proportional to
the number of targeted regions in the kit. The total number of targeted
regions is given under the name flag of each sphere.
Additional file 2: Capture details of the CCDS exons for Agilent
SureSelect in the control I sample. Tabular file listing CCDS annotated
exons, their targeting in the Agilent SureSelecet kit and mean
sequencing coverage for the control I sample.
Additional file 3: Capture details of the CCDS exons for Agilent
SureSelect 50 Mb in the control I sample. Tabular file listing CCDS
annotated exons, their targeting in the Agilent SureSelecet 50 Mb kit and
mean sequencing coverage for the control I sample.
Additional file 4: Capture details of the CCDS exons for NimbleGen
SeqCap in the control I sample. Tabular file listing CCDS annotated
exons, their targeting in the NimbleGen SeqCap kit and mean
sequencing coverage for the control I sample.
Additional file 5: Capture details of the CCDS exons for NimbleGen
SeqCap v2.0 in the control I sample. Tabular file listing CCDS
annotated exons, their targeting in the NimbleGen SeqCap v2.0 kit and
mean sequencing coverage for the control I sample.
Additional file 6: Comparison of poorly captured targets between
the exome capture kits. Table presenting comparisons between the
regions of the common target with poor capture success in one kit
(mean sequencing coverage 0×) and reasonable capture success in
another kit (mean sequencing coverage ≥ 10×).
Additional file 7: Mean allele balances for heterozygous single
nucleotide variants. (a-e) Allele balances are given for the heterozygous
SNVs in the whole genome (a), in each exome capture method’s own
CTR (b), in each exome capture method’s own CTR and flanking the 100
bp (c), in the CCDS annotated exon regions (d) and the common
regions targeted for capture in all the methods (e) for different minimum
sequencing coverages. In (a, b), allele balances are given for the control I
sample (bars without outline) and for the mean values from the 26
additional exome samples (bars with thick outline). The ideal allele
balance of 0.5 is indicated with a red line. Regions including mostly non-
targeted base pairs, as in the whole genome and CTR + flanking regions,
had a mean allele balance closer to 0.5 than the regions with only
targeted base pairs. Additionally, allele balance was shifted away from
the 0.5 with increasing minimum sequencing depth.
Additional file 8: Correlation of VCP genotype calls from Agilent
SureSelect- and NimbleGen SeqCap-captured (a) and SureSelect 50
Mb- and SeqCap v2.0-captured (b) sequenced genotypes to the
Illumina Human660W-Quad v1 SNP chip genotypes with exact
sequencing coverages. Correlations for heterozygous, reference
homozygous and variant homozygous SNPs (according to the chip
genotype call) are presented in separate graphs, though graphs lying
near 100% correlation cannot be visualized. The x-axis represents the
exact coverage of the sequenced SNPs.
Additional file 9: Correlation of SAMtools’ pileup genotype calls (a,
b) and GATK genotype calls (c, d) from Agilent SureSelect- and
NimbleGen SeqCap-captured and SureSelect 50 Mb- and SeqCap
v2.0-captured sequenced genotypes to the Illumina Human660W-
Quad v1 SNP chip genotypes. The SAMtools’ pileup genotype calls
correlated worse with the chip genotypes than the genotypes
accommodated with the quality ratios. Correlations for heterozygous,
reference homozygous and variant homozygous SNPs (according to the
chip genotype call) are presented in separate graphs, though graphs
lying near 100% correlation cannot be visualized. The x-axis represents
the accumulative coverage of the sequenced SNPs.
Additional file 10: Examined disorders of the Finnish disease
heritage, their mutation loci and the sequencing coverage of
control sample I on the loci.
Additional file 11: Sample preparation workflows for sample
preparation I (a) and sample preparation II (b). (a) Orange boxes
represent the protocol provided by Agilent for the SureSelect Human All
Exon capture kit, and green boxes the protocol for the SeqCap EZ
Exome capture kit by NimbleGen. Protocol simplifications and
equalizations were made in the sample preparation, and are represented
as blue boxes and arrows. (b) Similarly for sample preparations II, orange
boxes refer to Agilent SureSelect 50 Mb and green boxes to NimbleGen
SeqCap v2.0. Not all the steps of the provided protocols are represented.
Abbreviations
bp: base pair; BWA: Burrows-Wheeler Aligner; CCDS: Consensus Coding
Sequence; CTR: capture target region; GATK: Genome Analysis Toolkit; indel:
insertion-deletion; miRNA: microRNA; REA: read end anomaly; SNP: single
nucleotide polymorphism; SNV: single nucleotide variant; VCP: Variant Calling
Pipeline.
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